Расширенный поиск

Интенсивная терапия при муковисцидозе взрослых

Полный текст:

Об авторах

С. Н. Авдеев
НИИ пульмонологии М3


В. А. Самойленко
НИИ пульмонологии М3


Е. Л. Амелина
НИИ пульмонологии М3


А. Г. Чучалин
НИИ пульмонологии М3


Список литературы

1. Амелина Е.Л., Чучалин А.Г. Муковисцидоз: современный подход к диагностике и лечению. Рус. мед. журн. 1997; 5 (17): 1136—1142.

2. Капранов Н.И., Каширская Н.Ю. Актуальные проблемы муковисцидоза на современном этапе в России. Пульмонология 1997; 4: 7—16.

3. Amstrong J.B., White J.C. Liquification of viscous purulent exudates by deoxyribonuclease. Lancet 1950; 2: 739—742.

4. Anthonisen N.R. Pulmonary perspective. Hypoxemia and O2 therapy. Am. Rev. Respir. Dis. 1982; 125: 729—733.

5. Arens R., Gozal D., Omlin K.J. et at. Comparison of high frequency chest compression and convectional chest physiotherapy in hospitalized patients with chest fibrosis. Am. J. Respir. Crit. Care Med. 1994; 150: 1154—1157.

6. aubier м., dombert m.-c. acute exacerbation of chronic airflow obstruction. in: pinsky m.r., dhainaut j.-f.a., eds. pathophysiologic foundations of critical care. baltimore: williams & wilkins; 1991. 427—445.

7. Avital A., Sanchez I., Holbrow J. et at. Effect of theophylline on lung function tests , sleep quality, and nighttime SaÜ2 in children with cystic fibrosis. Am. Rev. Respir. Dis. 1991; 144: 1245—1249.

8. Baumann M.H., Strange C. Treatment of spontaneous pneumothorax. A more aggressive approach? Chest 1997; 112: 789—804.

9. Benson M.S., Pierson D.J. Auto-PEEP during mechanical ventilation of adults. Respir. Care 1988; 33: 557—565.

10. Bilton D., Webb A.K., Foster H. et at. Life threatening haemoptysis in cystic fibrosis: an alternative therapeutic approach. Thorax 1990; 45: 975—976.

11. Branthwaite M.A. Non-invasive and domiciliary ventilation: positive pressure techniques. Ibid. 1991; 46: 208—212.

12. Brinson G.M., Noone P.G., Mauro M.A. et at. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 1998; 157: 1951—1958.

13. Brochará L. Non-invasive ventilation: practical issues. Intens. Care Med. 1993; 19: 431—432.

14. Brochard L. Noninvasive ventilation in acute respiratory failure. Respir. Care 1996; 41: 456—462.

15. Browning I.B., D’Alonzo G.E., Tobin M.J. Importance of respiratory rate as an indicator of respiratory dysfunction in patients with cystic fibrosis. Chest 1990; 97: 1317—1321.

16. Bryan C.L., Jenkinson S.G. Oxygen toxicity. Clin. Chest Med. 1988; 9: 141—152.

17. Burns J.L. Treatment of cepacia: In search of the magic bullet. Pediatr. Pulmonol. 1997; 14 (suppl.): 90—91.

18. Cannon W.B., Vierra M.A., Cannon A. Thoracoscopy for spontaneous pneumothorax. Ann. Thorac. Surg. 1993; 56: 686—687.

19. Caronia C.G., Silver P., Nimkoff L. et al. Use of bilevel positive airway pressure (BIPAP) in end-stage patients with cystic fibrosis awaiting lung transplantation. Clin. Pediatr. (Philad.) 1998; 37: 555—559.

20. Connors A.F.Jr., McCaffree D.R., Gray B.A. Effect of inspiratory flow rate on gas exchange during mechanical ventilation. Am. Rev. Respir. Dis. 1981; 124: 537—543.

21. Cotromanes E., Gerrity T.R., Garrard C.S. et al. Aerosol penetration and mucociliary transport in the healthy human lung: effect of low serum theophylline levels. Chest 1985; 88: 111—114.

22. Cohen A.M. Haemoptysis — role of angiography and embolization. Pediatr. Pulmonol. 1992; 8 (suppl.): 85—86.

23. Conlan A.A., Hurwitz S.S. Management of massive haemoptysis with the rigid bronchoscope and cold saline lavage. Thorax 1980; 35: 901—904.

24. Conway S.P., Watson A. Nebulised bronchodilators, corticosteroids, and rhDNase in adult patients with cystic fibrosis. Ibid. 1997; 52 (suppl.2): S64—S68.

25. Crocco J.A., Rooney J.J., Fankushen D.S. et al. Massive haemoptysis. Arch. Intern. Med. 1968; 121: 495—498.

26. Cropp G.J. Effectiveness of bronchodilators in cystic fibrosis. Am. J. Med. 1996; 100 (1A): 19S—29S.

27. Davis P.B., di SanVAgnese P.A. Assisted ventilation for patients with cystic fibrosis. J.A.M.A. 1978; 239: 1851.

28. Davis P.B., Drumm M., Konstan M.W. Cystic fibrosis. Am. J. Respir. Crit. Care Med. 1996; 154: 1229—1256.

29. Dellinger R.P. Fiberoptic bronchoscopy in acute respiratory failure. In: Kirby R.R., Taylor R.W., eds. Respiratory failure. Chicago: Year Book Medical Publishers, Inc.; 1988. 434—447.

30. Dodge J.A., Morison S., Lewis P.A. et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968—95: UK Cystic Fibrosis Survey Mangement Committee. Arch. Dis. Child. 1997; 77: 493—496.

31. Editorial. Life-threatening haemoptysis. Lancet 1987; i: 1354—1356.

32. Egan T.M. Treatment of pneumothorax in the context of lung transplantation. Pediatr. Pulmonol. 1992; 8 (suppl.): 80—81.

33. Falk M., Andersen J.B. Positive expiratory pressure (PEP) mask. In: Pryor J.A., ed. Respiratory care. London: Churchill & Livingstone; 1991. 51—63.

34. Faroux B., Baculard A., Boule M., Tournier G. La ventilation non-invasive par masque nasal dans la mucoviscidose. Rev. Mai. Respir. 1995; 12: 509—511.

35. Fiel S.B. Clinical management of pulmonary disease in cystic fibrosis. Lancet 1993; 341: 1070—1074.

36. Finnegan M.J., Hughes D.V., Hodson M.E. Comparison of nebulized and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis. Eur. Respir. J. 1992; 5: 1089—1091.

37. FitzSimmons S.C. The changing epidemiology of cystic fibrosis. J. Pediatr. 1993; 122: 1—9.

38. Ganassini A., Rossi A. Physiological and clinical consequences of positive end-expiratory pressure. Monaldi Arch. Chest Dis. 1997; 52: 68—70.

39. Govan J.R.W. Burkholderia cepacia epidemiology: What we’ve learned, what remains contentious. Pediatr. Pulmonol. 1997; 14 (suppl.): 86—87.

40. Gozal D. Nocturnal ventilatory support in patients with cystic fibrosis: comparison with supplemental oxygen. Eur. Respir. J. 1997; 10: 1999—2003.

41. Graf-Deuel E., Knoblauch A. Simultaneous bilateral spontaneous pneumothorax. Chest 1994; 105: 1142—1146.

42. Granton J.T., Kesten S. The acute effects of nasal positive pressure ventilation in patients with advanced cystic fibrosis. Ibid. 1998; 113: 1013—1018.

43. Haetiel J.B., Moore F A ., Moore E.E., Read R.A. Efficacy of selective intrabronchial air insufflation in acte lobar collapse. Am. J. Surg. 1992; 164: 501—505.

44. Harada K., Mutsuda T., Saoyama N. et al. Reexpansion of refractory atelectasis using a bronchoscope with a ballon. Chest 1983; 84: 725—728.

45. Henke K.G., Regnis J.A., Bye P.T.P. Benefits of continuous positive airway pressure during exercise in cystic fibrosis and relationship to disease severity. Am. Rev. Respir. Dis. 1993; 148: 1272—1276.

46. Hill. N.S. Noninvasive ventilation. Does it work, for whom, and how? 1993; 147: 1050—1055.

47. Hodson M.E. Adults. Complication. In: Hodson M.E., Geddes D.M., eds. Cystic fibrosis. London: Chapman & Hall; 1995: 246—257.

48. Hodson M.E., Madden B.P., Steven M.H. et al. Non-invasive mechanical ventilation for cystic fibrosis patients — a potential bridge to transplantation. Eur. Respir. J. 1991; 4: 524—527.

49. Hodson M.E., Shah P.L. DNase trials in cystic fibrosis. Ibid. 1995; 8: 1786—1791.

50. Holdiness M.R. Clinical pharmacokinetics of N-acetylcysteine. Clin. Pharmacokinet. 1991; 20: 123—134.

51. Jett J.R., Tazelaar H.D., Keitn L.W., Ingrassia T.S. Plastic bronchitis: an old disease revisited. Mayo Clin. Proc. 1991; 66: 305—311.

52. Kearns G.L. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions. Ann.Pharmacother. 1993; 27: 74—79.

53. King M. Mucoactive therapy: What the future holds for patients with cystic fibrosis. Pediatr. Pulmonol. 1997; 14 (suppl): 122—123.

54. Koch C., Hoibij N. Pathogenesis of cystic fibrosis. Lancet 1993; 341: 1065—1069.

55. Madden B.P., Siddiqi A.J., Moran F. et al. The role of nasal intermittent positive pressure ventilation (NIPPV) in cystic fibrosis patients. Eur. Respir. J. 1996; 9 (suppl.): 238S.

56. Mal H., Rullon I., Mellot F. et al. Immediate and long-term results of bronchial artery embolization for life-threatening hemoptysis. Chest 1999; 115: 996—1001.

57. Marcus C.L., Bader D., Stabile M.W. et al. Supplemental oxygen and exercise performance in patients with cystic fibrosis with severe pulmonary disease. Ibid. 1992; 101: 52—57.

58. Marini J.J., Capps J.S., Culver B.H. The inspiratory work of breathing during assisted mechanical ventilation. Ibid. 1985; 87: 612—618.

59. Matthay R.A., Berger H.J., Loke J. et al. Effects of theophylline upon right and left ventricular performance in chronic obstructive pulmonary disease. Am. J. Med. 1978; 65: 903—910.

60. Matthay M.A., Hopewell P.C. Acute respiratory failure. In: George R.B. et al., eds. Chest medicine. Essentials of pulmonary and critical care medicine. Baltimore: Williams & Wilkins; 1990. 413—437.

61. Meduri G.U., Turner R.E., Abou-Shala N. et al. Noninvasive positive pressure ventilation via face mask. First-line intervention in patients with acute hypercapnie and hypoxemic respiratory failure. Chest 1996; 109: 179—193.

62. Myers D.L. Pharmacologic therapy of respiratory failure. In: Kirby R.K., Taylor R.W., eds. Respiratory failure.Chicago: Year Book Medical Publishers Inc.; 1988. 478—495.

63. Noppen M., Dhondt E., Mahler T. et al. Successful management of recurrent pneumothorax in cystic fibrosis by localized apical thoracoscopic talc poudrage. Chest 1994; 106: 262—264.

64. Noyes B.E., Orenstein D.M. Treatment of pneumothorax in cystic fibrosis in the era of lung transplantation. Ibid. 1992; 101: 1187—1188.

65. Oberwaldner B., Theissl B., Rucker A., Zach M.S. Chest physiotherapy in hospitalized patients with cystic fibrosis: a study of lung function effects and sputum production. Eur. Respir. J. 1991; 4: 152—158.

66. O'Donnell D.E., Sanii R., Anthonisen N.R., Younes M. Effect of dynamic airway compression on breathing pattern and respiratory sensation in severe chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1987; 135: 912—918.

67. Orebaugh S.L. Initiation of mechanical ventilation in the emergency department. Am. J. Emerg. Med. 1996; 14: 59—69.

68. Padman R., Von Nessen S., Goodill J. et al. Noninvasive mechanical ventilation for cystic fibrosis patients with end stage disease. Respir. Care 1994; 39: 736—739.

69. Page C.P. Theophylline as an anti-inflammatory agent. Eur. Respir. Rev. 1996; 6: 74—78.

70. Patel U., Pattison C.W., Raphael M. Management of massive haemoptysis. Br. J. Hosp. Med. 1994; 52: 74—78.

71. Pedersen S. Inhalers and nebulizers: which to choose and why. Respir. Med. 1996; 90: 69—77.

72. Penketh A.R., Knight R.K., Hodson M.E., Batten J.C. Management of pneumothorax in adults. Thorax 1982; 37: 850—853.

73. Peruzzi W.T. The current s ta tu s of PEEP. Respir. Care 1996; 41: 273—281.

74. Petroj B Eegare M., Goldberg P. et al. Continuous positive airway pressure reduces work of breathing and dyspnea during weaning from mechanical ventilation in severe chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1990; 141: 281—289.

75. Piper A.i., Parker S., Torzillo P.J. et al. Nocturnal nasal IPPV stabilizes patients with cystic fibrosis and hypercapnic respiratory failure. Chest 1992; 102: 846—850.

76. Poggi R., Masotti A., Rossi A. Acute respiratory failure. Monaldi Arch. Chest Dis. 1994; 49: 488—492.

77. Pryor J.A. The forced expiration technique. In: Pryor J.A., ed. Respiratory care. London: Churchill Livingstone; 1991. 79—100.

78. Pursel S.E., Lindsky G.E. Haemoptysis: a clinical evaluation of 105 patients examined consecutively on a thoracic surgical service. Am. Rev. Respir. Dis. 1961; 84: 329—336.

79. Ramsey B.W. Management of pulmonary disease in patients with cystic fibrosis. N. Engl. J. Med. 1996; 335: 179—188.

80. Ramsey B.W., Wentz K.R., Smith A.L. et al. Predictive value of oropharingeal cultures for identifying lower airway bacteria in cystic fibrosis patients. Am.Rev.Respir.Dis. 1991; 144: 331—337.

81. Redondo P., Subira M.L. N-acetylcysteine inhibits production of Tumor Necrosis Factor a and Interleukin-1 p. Arch. Intern. Med. 1996; 156: 1238—1241.

82. Regelmann W.E., Elliott G.R., Warwick W.J., Clawson C.C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am. Rev. Respir. Dis. 1990; 141: 914—921.

83. Regnis J.A., Piper A.J., Henke K.G. et al. Benefits of nocturnal nasal CPAP in patients with cystic fibrosis. Chest 1994; 106: 1717—1724.

84. Robotham J.L. Cystic fibrosis. In: Kirby R.R., Taylor R.W., eds. Respiratory failure. Chicago: Year Book Medical Publishers Inc.; 1988. 160—168.

85. Rossi A., Polese G., Brandi G., Conti G. Intrinsic positive end-expiratory pressure (PEEPi). Intensive Care Med. 1995; 21: 522—536.

86. Rubin B.K. The classification and use of mucoactive medications. Pediatr. Pulmonol. 1997; 14 (suppl.): 118—119.

87. Sanchez I., Holbrow J., Chernick V. Acute bronchodilator responce to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis. J. Pediatr. 1992; 120: 486—488.

88. Saumench J., Escarrabil J., Padro L. et al. Value of fiberoptic bronchoscopy and angiography for diagnosis of the bleeding site in haemoptysis. Ann. Thorac. Surg. 1989; 48: 272—274.

89. Shaad U.B., Wedgwood-Krucko J., Suter S., Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J. Pediatr. 1987; 111: 599—605.

90. Shidlow D., Taussig L., Knowles M. Consensus conference: pulmonary complications of cystic fibrosis. Cystic Fibros. Found. 1991 ; 2:1 - 18 .

91. Slutsky A.S. Mechanical ventilation. Chest 1993; 104: 1833—1859.

92. Smith R.A. Oxygen delivery systems. In: Kirby R.R., Taylor R.W., eds. Respiratory failure. Chicago: Year Book Medical Publishers Inc.; 1988. 515—529.

93. Spector M., Stern R. Pneumothorax in cystic fibrosis: a 26-year experience. Ann. Thorac. Surg. 1989; 47: 204—207.

94. Sweeney N., Fellows K. Bronchial artery embolization for severe haemoptysis in cystic fibrosis. Chest 1990; 97: 1322—1326.

95. Swersky R.B., Chang J.B., Wisoff G.B., Gorvoy J. Endobronchial ballon tamponade of haemoptysis in patients with cystic fibrosis. Ann. Thorac. Surg. 1979; 27: 262—264.

96. Susini G., Sisillo E., Bortone F. et al. Postoperative atelectasis reexpansion by selective insufflution through a ballon-tipped catheter. Chest 1992; 102: 1693—1696.

97. Tan R.T., McGahan J.P., Link D.P., Lantz B.M.T. Bronchial artery embolization in management of haemoptysis. J. Intervent. Radiol. 1991; 6: 67—76.

98. Tobin M.J. Mechanical ventilation. N. Engl. J. Med. 1994; 330: 1056—1061.

99. Tonkin I.L., Hanissian A.S., Boulden T.F. et al. Bronchial arteriography and embolotherapy for hemoptysis in patients with cystic fibrosis. Cardiovasc. Intervent. Radiol. 1991; 14: 241—246.

100. Town D.J., Brimicotnbe R.W., Hodson M.E. et al. Inhalation of antibiotics in cystic fibrosis. Eur. Respir. J. 1995; 8: 1594—1604.

101. Tsao T.C., Tsai Y.H., Lan R.S. et al. Treatment for collapsed lung in critically ill patients. Selective intrabronchial air insufflation using the fiberoptic bronchoscope. Chest 1990; 97: 435—438.

102. Tsncamoto T., Sasaki FI., Nakamura FI. Treatment of haemoptysis patients by thrombin and fibrinogen-thrombin infusion th erapy using a fiberoptic bronchoscope. Ibid. 1989; 96: 473—476.

103. van Harren E.H., Lammers J.W., Festen J., van Herwaarden C.L. Bronchial vagal tone and responsiveness to histamine, exercise and bronchodilators in adult patients with cystic fibrosis. Eur. Respir. J. 1992; 5: 1083—1088.

104. Wanke Т., Mercle М., Zifko U. et al. The effect of aminophylline on the force-lenth characteristics of the diaphragm. Amer. J. Respir. Crit. Care Med. 1994; 149: 1545—1549.

105. Wanner A., Landa J.F., Nieman R.E. et al. Bedside bronchofiberscopy for atelectasis and lung abscess. J.A.M.A. 1973; 224: 1281—1285.

106. Warwick W.J., Hansen L.G. The long-term effect of high-frequency chest compression therapy on pulmonary complications of cystic fibrosis. Pediatr. Pulmonol. 1991; 11: 265—271.

107. Wasserman K. Uses of oxygen in the trea tm en t of acute respiratory failure secondary to obstructive lung disease. Monaldi Arch. Chest Dis. 1993; 48: 509—514.

108. Wedzicha J.A., Pearson M.C. Management of massive haemoptysis. Respir. Med. 1990; 84: 9—12.

109. Wilmott R. The DNase multicentre study group and Genetech staff. A phase II double-blind multicentre study of the safety and efficacy of aerosolised recombinant human DNase 1 in hospitalized patients with cystic fibrosis experiencing acute pulmonary exacerbation. Pediatr. Pulmonol. 1993; 9 (suppl.): 154.

110. White R.I. Bronchial artery embolotherapy for control of acute hemoptysis analysis of outcome. Chest 1999; 115: 912—915.

111. Wood R.E., Wanner A., Hirsch J., Farrel P.M. Tracheal mucociliary transport in cystic fibrosis and its stimulation by terbutaline. Am. Rev. Respir. Dis. 1975; 111: 733—738.

112. Wood R.E. Haemoptysis in cystic fibrosis. Pediatr.Pulmonol. 1992; 8 (suppl.): 82—84.

113. Behrman. Nelson Textbook of Pediatrics. 16-th Edition. W.B.Saunders Company, 2000.


Для цитирования:

Авдеев С.Н., Самойленко В.А., Амелина Е.Л., Чучалин А.Г. Интенсивная терапия при муковисцидозе взрослых. Пульмонология. 2001;(3):87-99.

For citation:

Avdeev S.N., Samoilenko V.A., Amelina E.L., Chuchalin A.G. Intensive care for adult cystic fibrosis patients. PULMONOLOGIYA. 2001;(3):87-99. (In Russ.)

Просмотров: 97

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution-NonCommercial 4.0 International.

ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)